Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children

Doaa Elsherbiny, Yuan Ren, Helen McIlleron, Gary Maartens, Ulrika S H Simonsson, Doaa Elsherbiny, Yuan Ren, Helen McIlleron, Gary Maartens, Ulrika S H Simonsson

Abstract

Purpose: The population pharmacokinetics (PK) of lopinavir in tuberculosis (TB)/human immunodeficiency virus (HIV) co-infected South African children taking super-boosted lopinavir (lopinavir/ritonavir ratio 1:1) as part of antiretroviral treatment in the presence of rifampicin were compared with the population PK of lopinavir in HIV-infected South African children taking standard doses of lopinavir/ritonavir (ratio 4:1).

Methods: Lopinavir concentrations were measured in 15 TB/HIV-co-infected paediatric patients who were sampled during and after rifampicin-based TB treatment and in 15 HIV-infected children without TB. During TB therapy, the dose of ritonavir was increased to lopinavir/ritonavir 1:1 in order to compensate for the induction of rifampicin. The children received median (interquartile range=IQR) doses of lopinavir 292 mg/m(2) (274, 309) and ritonavir 301 mg/m(2) (286, 309) twice daily. After TB treatment completion the children received standard doses of lopinavir/ritonavir 4:1 (median [IQR] lopinavir dose 289 mg/m(2) [286, 303] twice daily) as did those without TB (median [IQR] lopinavir dose 265 mg/m(2) [249, 289] twice daily).

Results: Lopinavir oral clearance (CL/F) was about 30% lower in children without TB than in co-infected children treated with super-boosted lopinavir. However, the predicted lopinavir C(min) was above the recommended minimum therapeutic concentration during TB/HIV co-treatment in the 15 children. Lopinavir CL/F increased linearly during the dosing interval.

Conclusions: Increasing the ritonavir dose to achieve a lopinavir/ritonavir ratio of 1:1 when given in combination with rifampicin-based TB treatment did not completely compensate for the enhancement of lopinavir CL/F caused by rifampicin. The time-dependent lopinavir CL/F might be due to a time-dependent recovery from ritonavir inhibition of lopinavir metabolism during the dosing interval.

References

    1. Nutrition. 2006 Mar;22(3):245-51
    1. Clin Pharmacokinet. 2002;41(14):1115-33
    1. J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):566-9
    1. Clin Pharmacol Ther. 2006 Mar;79(3):243-54
    1. Med Sci Monit. 2004 Jan;10(1):RA5-14
    1. Clin Pharmacokinet. 2003;42(9):819-50
    1. Xenobiotica. 2007 Oct-Nov;37(10-11):1225-56
    1. Drug Metab Dispos. 2002 Jul;30(7):795-804
    1. J Pharmacol Exp Ther. 2001 Dec;299(3):849-57
    1. Antimicrob Agents Chemother. 2004 May;48(5):1553-60
    1. Antimicrob Agents Chemother. 2009 Jun;53(6):2532-8
    1. J Clin Pharmacol. 1997 Jun;37(6):486-95
    1. AIDS. 2008 Jan 11;22(2):249-55
    1. Br J Clin Pharmacol. 2005 Feb;59(2):174-82
    1. Am J Clin Nutr. 2003 Aug;78(2):319-25
    1. Clin Infect Dis. 2006 Apr 1;42(7):1040-7
    1. Antivir Ther. 2007;12(4):453-8
    1. Int J Tuberc Lung Dis. 2002 Aug;6(8):672-8
    1. Br J Clin Pharmacol. 1998 Aug;46(2):111-6
    1. Comput Methods Programs Biomed. 1999 Jan;58(1):51-64
    1. J Assoc Nurses AIDS Care. 2001 Mar-Apr;12(2):101-4
    1. Antimicrob Agents Chemother. 2006 Nov;50(11):3548-55
    1. Pharmacotherapy. 2000 Jan;20(1):93-4
    1. Clin Pharmacokinet. 2008;47(10):681-92
    1. Antimicrob Agents Chemother. 2004 Apr;48(4):1073-81
    1. Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):741-7
    1. Clin Pharmacol Ther. 2007 Jan;81(1):69-75
    1. Br J Clin Pharmacol. 2005 Oct;60(4):378-89

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner